Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike
Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike
Simple item page
Full item details
- dc.contributor.author
- Prévost, Jérémie
- Gasser, Romain
- Beaudoin-Bussières, Guillaume
- Richard, Jonathan
- Duerr, Ralf
- Laumaea, Annemarie
- Anand, Sai Priya
- Goyette, Guillaume
- Benlarbi, Mehdi
- Ding, Shilei
- Medjahed, Halima
- Lewin, Antoine
- Perreault, Josée
- Tremblay, Tony
- Gendron-Lepage, Gabrielle
- Gauthier, Nicolas
- Carrier, Marc
- Marcoux, Diane
- Piché, Alain
- Lavoie, Myriam
- Benoit, Alexandre
- Loungnarath, Vilayvong
- Brochu, Gino
- Haddad, Elie
- Stacey, Hannah D.
- Miller, Matthew S.
- Desforges, Marc
- Talbot, Pierre J.
- Gould Maule, Graham T.
- Côté, Marceline
- Therrien, Christian
- Serhir, Bouchra
- Bazin, Renée
- Roger, Michel
- Finzi, Andrés
- dc.date.accessioned
- 2024-07-05T14:36:06Z
- dc.date.available
- 2024-07-05T14:36:06Z
- dc.date.issued
- 2020-10-20
- dc.description.abstract - en
- SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
- dc.identifier.doi
- https://doi.org/10.1016/j.xcrm.2020.100126
- dc.identifier.issn
- 2666-3791
- dc.identifier.pubmedID
- 33015650
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/2653
- dc.language.iso
- en
- dc.publisher
- Elsevier Inc.
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.openaccesslevel - en
- Gold
- dc.rights.openaccesslevel - fr
- Or
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike
- dc.type - en
- Article
- dc.type - fr
- Article
- local.acceptedmanuscript.articlenum
- 100126
- local.article.journalissue
- 7
- local.article.journaltitle
- Cell Reports Medicine
- local.article.journalvolume
- 1
- local.pagination
- 1-8, e1-e4
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: prevost-cross-sectional-evaluation-of-humoral-responses-against-sars-cov-2-spike.pdf
Size: 1.82 MB
Format: PDF
Collection(s)